Medicare GLP-1 Bridge Day One: What Actually Happened

The Medicare GLP-1 Bridge program launched on July 1, 2026. After months of anticipation, confusion, and a mountain of FAQs from CMS, the program is now live. Here's what's actually happening on the ground — and what it means if you're currently using compounded GLP-1 medications.

What the Bridge Actually Is

The Medicare GLP-1 Bridge is a time-limited CMS demonstration program — not a permanent benefit. It operates entirely outside the standard Medicare Part D coverage structure. Your Part D plan doesn't manage it, doesn't pay for it, and doesn't need to opt in. Instead, CMS is using Humana as a central processor to handle prior authorizations, claims adjudication, and pharmacy payments.

The covered medications are specific: Wegovy (all injection and tablet formulations), Zepbound (KwikPen formulation only — single-dose vials and pens are excluded), and Foundayo (all formulations). These are only covered when prescribed for weight management — not for type 2 diabetes, obstructive sleep apnea, or MASH, which remain covered under standard Part D.

Eligibility: Who Actually Qualifies

You must be enrolled in Medicare Part D — either through a standalone PDP or a Medicare Advantage plan with drug coverage. You must be 18 or older. And you must meet one of the clinical criteria at the time you first started GLP-1 therapy (even if that was before the Bridge launched):

• BMI of 35 or greater (no additional diagnosis required)
• BMI of 30 or greater with heart failure, uncontrolled hypertension, or chronic kidney disease
• BMI of 27 or greater with pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease

Day One: What Patients Are Experiencing

The prior authorization process is where most of the friction is occurring. Here's the workflow as designed:

1. Your provider writes a prescription for an eligible GLP-1 and sends it to your pharmacy
2. The pharmacy submits the claim using a specific BIN and PCN designated for the Bridge program
3. If the claim is rejected (which it will be on first submission without prior auth), the pharmacy receives instructions to request prior authorization
4. The pharmacy sends a prior authorization fax form to your provider
5. Your provider completes the form and faxes it to the Bridge program's central processor
6. Once approved, subsequent fills don't require new authorization — unless you switch medications

Reports from the first 48 hours suggest the most common issues are: pharmacists submitting claims to the patient's Part D plan instead of the Bridge processor, providers not yet having the prior authorization fax form, and general confusion about whether to process through Part D or the Bridge. CMS anticipated this — their prescriber guidance specifically warns that if a pharmacist doesn't receive the Bridge-specific billing direction, they might default to the Part D plan.

What This Means for Compounded GLP-1 Users

If you're currently on compounded semaglutide or tirzepatide and you're on Medicare, the Bridge might offer a cheaper pathway — $50/month is lower than most compounded options. But several important caveats apply:

The critical question is what happens after December 2027. CMS originally planned to transition into the BALANCE Model for permanent Part D coverage, but that program has been delayed indefinitely. If the Bridge ends without a successor, patients who switched from compounded to brand may need to find new access pathways — potentially at much higher prices.

Who Should Switch — and Who Should Wait

The Bridge makes financial sense if you meet all eligibility criteria and are comfortable with the available dose options. But if you've been titrating on custom compounded doses (for example, a 1.25mg semaglutide dose that falls between the standard 1.0mg and 1.7mg pen options), the forced jump to a brand pen dosage may cause increased side effects.

Our recommendation: if you qualify, talk to your provider about the Bridge. Run the numbers for your specific situation. And if you switch, maintain your relationship with your compounding pharmacy — the regulatory landscape is still shifting, and having a backup pathway is prudent through 2027 and beyond.